NYSE:CLAA Colonnade Acquisition Corp. II (CLAA) Stock Price, News & Analysis → Why Big Pharma is Investing Billions in This Biotech (From Behind the Markets) (Ad) Free CLAA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.20▼$10.2150-Day Range$10.15▼$10.2152-Week Range$9.72▼$10.21Volume653,302 shsAverage Volume199,823 shsMarket Capitalization$420.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Colonnade Acquisition Corp. II alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Colonnade Acquisition Corp. II Stock (NYSE:CLAA)Colonnade Acquisition Corp. II focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in West Palm Beach, Florida.Read More Ad Behind the MarketsWhy Big Pharma is Investing Billions in This BiotechIf you're on the hunt for a great biotech stock under $20... you need to see this video.Watch my exclusive report here>>> CLAA Stock News HeadlinesAugust 12, 2021 | investing.comColonnade Acquisition II Corp (CLAA)See More Headlines Receive CLAA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Colonnade Acquisition Corp. II and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNYSE:CLAA CUSIPN/A CIK1837739 Webwww.claacq.com Phone561-712-7860FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-10.02% Return on Assets0.52% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.09 per share Price / Cash Flow112.83 Book Value($0.53) per share Price / Book-19.25Miscellaneous Outstanding Shares41,250,000Free Float33,000,000Market Cap$420.75 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Remy White Trafelet (Age 52)CEO & Director Key CompetitorsResources ConnectionNASDAQ:RGPSezzleNASDAQ:SEZLLiquidity ServicesNASDAQ:LQDTSpree Acquisition Corp. 1NYSE:SHAPPriority TechnologyNASDAQ:PRTHView All Competitors This page (NYSE:CLAA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Colonnade Acquisition Corp. II Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
